Nonalcoholic steatohepatitis (NASH) is an aggressive fatty liver disease that can cause severe liver damage and severely impact overall health. There is currently no effective treatment for NASH, but recent studies have found that vitamin B12 and folic acid may help reduce inflammation and scarring in human and animal models.NASH Future research is needed to better understand why M. develops, and treatments can counteract the underlying mechanisms. Liver problems can occur for many reasons, but they are not always due to alcohol consumption.Non-alcoholic fatty liver disease (NAFLD) is caused by the accumulation of fat in the liver. A term used to describe various disorders. Regardless of the amount of alcohol consumed, NAFLD is caused by other factors, often causing inflammation and liver damage. In more severe or aggressive cases, NAFLD may be diagnosed as nonalcoholic steatohepatitis (NASH). Currently, there are no drugs that can treat non-alcoholic steatohepatitis. However, a recent study published in the Journal of Hepatology investigated the mechanism of NASH and found that a specific protein, syntaxin 17, was blocked from clearing dead and unhealthy cells. . In addition, researchers found that vitamin B12 and folic acid increased syntaxin 17 levels, which helped reduce fibrosis (thickening or scarring) and inflammation in the liver. The National Institute of Diabetes and Digestive Kidney Diseases (NIDDK) has identified the accumulation of fat in the liver as a hallmark of non-alcoholic fatty liver disease (NAFLD). Certain health conditions increase your risk of developing NAFLD, including:
Some people with NAFLD also develop liver damage and inflammation, which can lead to non-alcoholic steatohepatitis (NASH). NASH causes scarring and permanent liver damage, increasing the risk of liver cancer. Currently, there are no drugs that can effectively treat NASH. Jude Oben, a gastroenterologist and hepatologist at Guy's and St Thomas' NHS Foundation Trust in London, explained to MNT:
“Non-alcoholic fatty liver disease [NAFLD] is a disease that affects approximately 25% of the world's population. It is mainly associated with obesity. The more serious stage, non-alcoholic steatohepatitis (NASH), affects about 5% of the world's population. NASH can lead to cirrhosis, liver transplantation, and liver cancer. –Dr. Jude Oven, Gastroenterologist and Hepatologist
More research is needed to understand why NASH develops, and treatments can counteract the underlying mechanisms. The authors of the current study used human subjects, mouse models, and primates to examine the effects involved in the development of NASH. They found that there is an increase in the amino acid homocysteine (Hcy) associated with liver inflammation and fibrosis. Dr. Oben was interested in the information this study provided about NASH and non-alcoholic fatty liver disease. He states to his MNT:
“…A detailed experimental study just published by Tripathi and Colleagues (Journal of Hepatology, July 2022) provides a new view of these diseases. It has been clearly shown to reduce NASH liver inflammation and liver scarring (fibrosis).These agents appear to work by affecting the homocysteine pathway.This has been well studied. No way.Homocysteine appears to be metabolized down in NASH and up in NASH..." - Dr. Upper, study author
Study Author Dr. Paul M. Yen, a professor of medicine and member of the Duke Institute of Molecular Physiology in Durham, North Carolina, told MNT:
“…surprisingly, we found that vitamin therapy prevented and reversed adiposity, inflammation and fibrosis in two different NASH mouse models. It suggests that in patients with low folic acid levels and elevated serum homocysteine levels, vitamin therapy may be the first-line therapy.
This study provided excellent data in a research area with limited information. However, many of the studies have been in mouse models, so more research is needed to confirm the results and determine the best treatment for people diagnosed with NASH. The researchers suggest that vitamin B12 and folic acid, in particular, may be useful as preventive or first-line treatment for his NASH. Future clinical trials may investigate how vitamin B12 and folic acid may help her with NASH. Dr. Yen explained to MNT as follows.
"Our preclinical studies demonstrate that NASH patients with pernicious anemia, gastritis, previous gastric bypass surgery, diabetes and metformin intake, or vegetarians with low folic acid/B12 intake, may be exposed to NASH." Evaluate for serum B12, folic acid, and homocysteine levels, as they may benefit from vitamin B12 and folic acid therapy. Further clinical trials are needed to see if vitamin therapy improves NASH in these patients.” Paul M. Yen
#vitamin #health #neccesary
0 Comments